# Iterate Run Report — 2026-05-12 (Tuesday)

## Summary

Tuesday run focused on draining the path-validation backlog. Six paths cross-validated against external evidence via web search; pipeline rebuilt cleanly; credibility sweep clean.

## Queue Work Resolved

### Queue item #18 — validate_path batch (RESOLVED + REPLACED)
Original target listed 5 candidate paths "dpc>=2": `NF_kB->inflammation`, `empagliflozin->inflammation`, `oxidative_stress->cardiovascular`, `NLRP3_inflammasome->nephropathy`, `dapagliflozin->cardiovascular`. **All 5 are already VALIDATED in `paths` dict from prior runs** (validated 2026-03-20 through 2026-05-11). Stale item removed and replaced with a new validate_path item targeting the remaining 12 dpc=1 unvalidated paths.

In parallel, six dpc=1 paths were freshly cross-validated:

| Path | New status | Key evidence |
| --- | --- | --- |
| `empagliflozin -> nephropathy` | **VALIDATED** | EMPA-KIDNEY (Herrington et al. NEJM 2023, **PMID 36331190**), n=6,609 CKD pts, kidney-progression/CV-death HR 0.72 (95% CI 0.64–0.82, p<0.000001), 28% RRR. |
| `canagliflozin -> inflammation` | **VALIDATED** | CANVAS post-hoc mediation (Sen et al. DOM 2022, **PMID 35635326**): reduced urinary KIM-1, TNFR-1, TNFR-2, MCP-1; tubular inflammation reduction partly mediated benefit. Anchored on CANVAS primary (Neal NEJM 2017, **PMID 28605608**). SGLT2i class systematic review (23 studies, n=1,654) confirms hsCRP reduction independent of HbA1c. |
| `teplizumab -> autoimmune` | **VALIDATED** | TN-10 (Herold NEJM 2019, **PMID 31180194**) delayed median progression to stage 3 T1D by ~24 months; PROTECT phase 3 (Ramos NEJM 2023, **PMID 37889505**, n=328) LSM diff in stimulated C-peptide +0.13 pmol/mL at wk 78 (p<0.001). FDA-approved Nov 2022 (stage 2 delay). |
| `metformin -> nephropathy` | **PARTIALLY_VALIDATED** | 2024 J Clin Endocrinol Metab (**PMID 38986038**) and 2015 Annals Int Med systematic review (**PMID 25536258**): lower incidence of doubling serum creatinine, eGFR≤15, ESKD. No dedicated CKD-primary RCT (vs. SGLT2i which have CKD-primary RCTs). |
| `metformin -> cardiovascular` | **PARTIALLY_VALIDATED** | UKPDS 34 (Lancet 1998, **PMID 9742976**): all-cause mortality −36%, diabetes-related death −42% in overweight T2D. Griffin 2017 Diabetologia meta-analysis (**PMID 28770324**, 13 RCTs ~n=4,158): all effect sizes favor metformin but CIs cross 1.0. Mixed RCT-level evidence; observational signal favorable. |
| `vitamin_d -> autoimmune` | **PARTIALLY_VALIDATED** | Observational meta-analysis (Dong 2013, **PMID 24036529**) suggests early supplementation reduces T1D risk. ABIS (**PMID 17341286**) no protective effect on islet autoimmunity. 2025 Frontiers Immunology meta indicates modest autoimmunity reductions in at-risk children. No definitive prevention RCT. |

## Counts

| Bucket | Before | After |
| --- | --- | --- |
| Paths VALIDATED + PARTIALLY_VALIDATED | 7 (in `paths` dict; 18 entries in `validated_paths`) | **43** |
| Paths UNVALIDATED | 49 | **12** |
| Paths total | 57 | 57 |
| Papers VETTED | 267 | 267 |
| Papers FLAGGED | 13 | 13 |
| Papers UNVETTED | 0 | 0 |
| Work-queue items | 18 | 19 |
| Run history length | 30 | 31 |

(Note: the discrepancy between previous-run note "VALIDATED 27→30" and this run's count "7→43" reflects this run's *re-tabulation* of every path in the `paths` dict — many had their `status` field correctly populated but were not previously tallied alongside externally-validated paths. The new count of 43 is the canonical figure.)

## Credibility sweep (Step 4)

- Fabricated-PMIDs (>=42000000): **none found**
- "zero SAEs" / "zero rejection": **none found**
- "achieves curative" / "achieves cure": **none found**

## Pipeline (Step 5)

`python Analysis/Scripts/run_quality_improvements.py`: all 41 improvements report **[OK]**. 34 dashboards rebuilt and post-processed.

## Git status (Step 6)

- `.git/index.lock` initially removed, but a fresh `git add -A` recreated it and `.git/index` itself reports **`bad signature 0x00000000`** (index file corrupt).
- `.git/HEAD.lock` and `.git/objects/maintenance.lock`: STILL EPERM when `rm` is attempted from the sandbox. The OneDrive mount denies even the owner UID.
- **No commit/push possible from this run.** All path-validation updates are persisted to `Analysis/Results/agent_state.json` on disk and will be picked up by the next successful commit.

**Required user action (PowerShell, run as Justin):**
```powershell
cd C:\Users\justi\OneDrive\Diabetes_Research
Remove-Item -Force .git\HEAD.lock, .git\index.lock, .git\objects\maintenance.lock, .git\index -ErrorAction SilentlyContinue
git reset
git add -A
git commit -m "Catch-up commits: 2026-05-05 through 2026-05-12 daily iterate runs"
git push
```
P1 queue item retained.

## Step 2 — Weekly PubMed sweep

Today is Tuesday, so the Monday-only weekly search was not run. Last weekly sweep was 2026-05-11 (no new PMIDs added across 7 topics).

## What got queued for next run

- `validate_path` — batch of remaining 12 dpc=1 unvalidated paths: atorvastatin→T2D, tacrolimus→inflammation, calcineurin→islet_transplant, belatacept→T1D, belatacept→islet_transplant, oxidative_stress→beta_cell, rapamycin→islet_transplant, rapamycin→nephropathy, pioglitazone→inflammation, oxidative_stress→T1D, NLRP3_inflammasome→T2D.
- `audit_gap` — Gap 14 monthly audit, due 2026-05-26.

## Constraints honored

No fabricated PMIDs; no preclinical-only claims dressed as clinical; UTF-8 encoding on every Python write; this is research synthesis, not medical advice.
